Lilly Centre for Clinical Pharmacology
Singapore, 138623
NCT Number: NCT06916091
The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it.
The study will last approximately 10 weeks excluding a screening period.
Looking for future studies?
Notify Me21 year–65 year
All sexes
Interventional
Phase 1
Singapore, 138623
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered subcutaneously (SC)
Other names: LY3841136
Administered SC
Time frame: Baseline to Study Completion (Up to 10 Weeks)
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline to Study Completion (Up to 10 Weeks)
PK:Cmax of Eloralintide
Time frame: Baseline to Study Completion (Up to 10 Weeks)
PK: AUC of Eloralintide
Eli Lilly and Company
Industry
A Phase 1, Investigator- and Participant-Blinded, Placebo Controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT00342732
Body Weight, Nutrition Disorders
Phoenix, Arizona, United States
View Trial DetailsNCT00445627
Body Weight, Diabetes Mellitus
Bethesda, Maryland, United States
View Trial DetailsNCT06904105
Body Weight, Nutrition Disorders
Beijing, Beijing Municipality, China
View Trial Details